TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3029% below fair value
$1.81−0.10 (-5.24%)
Close on Nov 18, 2026Market cap $20.95MP/E –Yield –
TherapeuticsMD gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
TherapeuticsMD's gross profit for the twelve months ending Dec 31, 2023 was $1.30M, down 98.1% year over year. For fiscal 2023 it was $1.30M, down 98.1% from the year before. Over ten years it grew -15.3% a year on average. The highest annual figure on record is $68.57M in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.30M | -98.1% |
| FY2022 | Dec 31, 2022 | $68.57M | +5755.3% |
| FY2021 | Dec 31, 2021 | $1.17M | -97.6% |
| FY2020 | Dec 31, 2020 | $48.90M | +12.9% |
| FY2019 | Dec 31, 2019 | $43.31M | +224.1% |
| FY2018 | Dec 31, 2018 | $13.36M | -5.5% |
| FY2017 | Dec 31, 2017 | $14.14M | -6.8% |
| FY2016 | Dec 31, 2016 | $15.17M | -3.0% |
| FY2015 | Dec 31, 2015 | $15.64M | +37.7% |
| FY2014 | Dec 31, 2014 | $11.35M | +66.6% |
| FY2013 | Dec 31, 2013 | $6.82M | +176.0% |
| FY2012 | Dec 31, 2012 | $2.47M | +116.5% |
| FY2011 | Dec 31, 2011 | $1.14M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $502.00K | -99.3% |
| Q3 FY2023 | Sep 30, 2023 | -$53.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $437.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $416.00K | -97.1% |
| Q4 FY2022 | Dec 31, 2022 | $68.57M | +391.8% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $14.47M | -4.7% |
| Q4 FY2021 | Dec 31, 2021 | $13.94M | -18.0% |
| Q3 FY2021 | Sep 30, 2021 | $20.12M | +25.3% |
| Q2 FY2021 | Jun 30, 2021 | $18.87M | +199.5% |
| Q1 FY2021 | Mar 31, 2021 | $15.18M | +59.2% |
| Q4 FY2020 | Dec 31, 2020 | $17.00M | +30.5% |
| Q3 FY2020 | Sep 30, 2020 | $16.06M | -27.9% |
| Q2 FY2020 | Jun 30, 2020 | $6.30M | +30.5% |
| Q1 FY2020 | Mar 31, 2020 | $9.54M | +199.5% |
| Q4 FY2019 | Dec 31, 2019 | $13.02M | +214.6% |
| Q3 FY2019 | Sep 30, 2019 | $22.28M | +702.7% |
| Q2 FY2019 | Jun 30, 2019 | $4.83M | +46.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.18M | +1.4% |
| Q4 FY2018 | Dec 31, 2018 | $4.14M | +17.3% |
| Q3 FY2018 | Sep 30, 2018 | $2.78M | -25.3% |
| Q2 FY2018 | Jun 30, 2018 | $3.31M | -7.3% |
| Q1 FY2018 | Mar 31, 2018 | $3.14M | -5.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.53M | -6.6% |
| Q3 FY2017 | Sep 30, 2017 | $3.72M | -13.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.30M | – |
See a number that looks wrong?